Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Pharmacological targeting of CTPS1 elicits macrophage-mediated anti-leukemia immunity

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXin HeGMGuido Marcucci

Discussion

Loading...

Member takes

Overview

Treatment with STP-B improves macrophage polarization and reduces leukemia in mice, suggesting a new immune strategy.

Key Points

  • Treatment with STP-B significantly decreases leukemia burden in mice, promoting macrophage activity.
  • Flow cytometry analysis indicated an increase in CD11b⁺F4/80⁺ macrophages after STP-B treatment, highlighting immune response activation.
  • Observational analysis of acute myeloid leukemia and immune cell interaction demonstrates STP-B's potential in therapy.
  • These findings underscore the importance of targeted nucleotide metabolism in enhancing macrophage-mediated immunity.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dce0https://doi.org/10.1182/blood-2025-1490
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated Acute Myeloid Leukemia2025
  2. 2Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias2025
  3. 3ST2 promotes leukemia transformation by reshaping the immune landscape in Acute Myeloid Leukemia2025
  4. 4NAMPT in macrophages promotes multiple myeloma drug resistance through mitochondrial metabolic reprogramming and modulates immunosuppression via the SIRT1/STAT3/SPP1 axis.2025 · 1 citations
  5. 5Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming2025